Therapeutic Drug Monitoring in Children and Adolescents: Findings on Fluoxetine from the TDM-VIGIL Trial

Therapeutic Drug Monitoring in Children and Adolescents: Findings on Fluoxetine from the TDM-VIGIL Trial

Fluoxetine is the recommended first-line antidepressant in many therapeutic guidelines for children and adolescents. However, little is known about the relationships between drug dose and serum level as well as the therapeutic serum reference range in this age group. Within a large naturalistic obse...

Full description

Bibliographic Details
Main Authors: Michael Frey, Lukasz Smigielski, Elvira Tini, Stefanie Fekete, Christian Fleischhaker, Christoph Wewetzer, Andreas Karwautz, Christoph U. Correll, Manfred Gerlach, Regina Taurines, Paul L. Plener, Uwe Malzahn, Selina Kornbichler, Laura Weninger, Matthias Brockhaus, Su-Yin Reuter-Dang, Karl Reitzle, Hans Rock, Hartmut Imgart, Peter Heuschmann, Stefan Unterecker, Wolfgang Briegel, Tobias Banaschewski, Jörg M. Fegert, Tobias Hellenschmidt, Michael Kaess, Michael Kölch, Tobias Renner, Christian Rexroth, Susanne Walitza, Gerd Schulte-Körne, Marcel Romanos, Karin Maria Egberts
Format: Article
Language:English
Published: MDPI AG 2023-08-01
Series:Pharmaceutics
Subjects:
TDM
adolescents
depression
antidepressants
selective serotonin reuptake inhibitors
pharmacovigilance
Online Access:https://www.mdpi.com/1999-4923/15/9/2202

Similar Items

Similar Items